Managing patients with recurrent acute exacerbations of chronic bronchitis: a common clinical problem

References

• Gross CP, Anderson GF, Powe NR. The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med 1999;340:1881–7
   Google Scholar
• US Department of Health and Human Services, National Institutes of Health National Heart, Lung, and Blood Institute. Chronic Obstructive Pulmonary Disease. March 2003; NIH Publication No. 03–5229
   Google Scholar
• Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 2000;94:204–13
   Google Scholar
• Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418–22
   PubMed Web of Science ®Google Scholar
• Spencer S, Calverley PMA, Burge PS, Jones PW; ISOLDE Study Group. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:122–8
   PubMedGoogle Scholar
• Kanner RE, Anthonisen NR, Connett JE; Lung Health Study Research Group. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study Research Group. Am J Respir Crit Care Med 2001;164: 358–64
   Google Scholar
• Cosio MG, Hale KA, Niewoehner DE. Morphologic and morphometric effects of prolonged cigarette smoking on the small airways. Am Rev Respir Dis 1980;122:265–71
   Google Scholar
• Rutgers SR, Postma DS, ten Hacken NHT, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000;55:12–8
   PubMed Web of Science ®Google Scholar
• Obaji A, Murphy TF, Sethi S. Lung function decline in advanced COPD. Presented at the ATS International Conference; May 18–23, 2001; San Francisco, CA
   Google Scholar
• Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608–13
   PubMedGoogle Scholar
• Smith CB, Golden C, Kanner R, Renzetti Jr. AD. Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 1980;121: 225–32
   Google Scholar
• Ball P, Harris JM, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. QJM 1995;88:61–8
   Google Scholar
• Sethi S, Murphy TF. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:1969–1970
   PubMed Web of Science ®Google Scholar
• Chodosh S, Schreurs JM, Siami G, et al. Efficacy of oral ciprofloxacin vs clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 1998;27:730–8
   PubMed Web of Science ®Google Scholar
• Anzueto A, Rizzo JA, Grossman RF. The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis [letter]. Clin Infect Dis 1999;28:1344–5
   Google Scholar
• Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150:1646–52
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77–121
   PubMed Web of Science ®Google Scholar
• Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000;117:380S–5S
   Google Scholar
• Kainulainen L, Nikoskelainen J, Vuorinen T, et al. Viruses and bacteria in bronchial samples from patients with primary hypogammaglobulinemia. Am J Respir Crit Care Med 1999;159:1199–204
   PubMed Web of Science ®Google Scholar
• Diaz PT, King MA, Pacht ER, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000;132:369–72
   PubMed Web of Science ®Google Scholar
• Taylor DC, Cripps AW, Clancy RL. A possible role for lysozyme in determining acute exacerbation in chronic bronchitis. Clin Exp Immunol 1995;102:406–16
   Google Scholar
• Pilette C, Godding V, Kiss R, et al. Reduced epithelial expression of secretory component in small airways correlates with airflow obstruction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:185–94
   PubMed Web of Science ®Google Scholar
• Abe Y, Murphy TF, Sethi S, et al. Lymphocyte proliferative response to P6 of Haemophilus influenzae is associated with relative protection from exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:967–71
   PubMed Web of Science ®Google Scholar
• Bakri F, Brauer AL, Sethi S, Murphy TF. Systemic and mucosal antibody response to Moraxella catarrhalis after exacerbations of chronic obstructive pulmonary disease. J Infect Dis 2002;185:632–40
   PubMed Web of Science ®Google Scholar
• Balter MS. Recommendations on the management of chronic bronchitis: a practical guide for Canadian physicians. Can Med Assoc J 1994;151\(suppl 10):7–23
   Google Scholar
• Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992;146:1067–83
   PubMed Web of Science ®Google Scholar
• Zalacain R, Sobradillo V, Amilibia J, et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999;13:343–8
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999;116:40–6
   Google Scholar
• Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618–23
   PubMed Web of Science ®Google Scholar
• Obaji A, Sethi S. Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones? Drugs Aging 2001;18:1–11
   PubMed Web of Science ®Google Scholar
• Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis 1998;27: 764–70
   Google Scholar
• Jacobs MR, Bajaksouzian S, Zilles A, et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study. Antimicrob Agents Chemother 1999;43:1901–8
   PubMed Web of Science ®Google Scholar
• Dagan R, Johnson CE, McLinn S, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs azithromycin in acute otitis media. Pediatr Infect Dis J 2000;19:95–104
   PubMed Web of Science ®Google Scholar
• Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000;44:43–50
   PubMed Web of Science ®Google Scholar
• Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance. A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999;18:1–9
   Google Scholar
• Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747–50
   PubMed Web of Science ®Google Scholar
• Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000;31:1008–11
   PubMed Web of Science ®Google Scholar
• Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999;341:233–9
   PubMed Web of Science ®Google Scholar
• Weiss K, Restieri C, Gauthier R, et al. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis 2001;33:517–22
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards (NCCLS). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved NCCLS Standard. 5th edn. Wayne, PA: January 2000;20:M100–S10(M7)
   Google Scholar
• File Jr. TM. Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of b-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;34\(Suppl1):S17–26
   Google Scholar
• Gay K, Baughman W, Miller Y, et al. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis 2000;182:1417–24
   PubMed Web of Science ®Google Scholar
• Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000;31: 613–5
   Google Scholar
• Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia [letter]. N Engl J Med 2002;346:630–1
   PubMed Web of Science ®Google Scholar
• Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy [letter]. Chest 2000;118:1839–40
   Google Scholar
• Murphy TF. Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response. Microbiol Rev 1996;60:267–79
   PubMedGoogle Scholar
• Doern GV, Brueggemann AB, Pierce G, et al. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40:2884–6
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Ehrhardt AF, Jones RN. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the Respiratory Surveillance Program Study: microbiology from the medical office practice environment. Am J Med 2001;111(Suppl 9A):4S–12S
   Google Scholar
• Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999;14:1015–22
   PubMed Web of Science ®Google Scholar
• Cunha BA. Ertapenem: a review of its microbiologic, pharmaco-kinetic and clinical aspects. Drugs Today 2002;38:195–213
   PubMed Web of Science ®Google Scholar
• Braun BL, Fowles JB. Characteristics and experiences of parents and adults who want antibiotics for cold symptoms. Arch Fam Med 2000;9:589–95
   PubMedGoogle Scholar
• Vanden Eng J, Marcus R, Hadler JL, Imhoff B, Vugia DJ, Cieslak PR, et al. Consumer attitudes and use of antibiotics. Emerg Infect Dis 2003;9:1128–35
   PubMed Web of Science ®Google Scholar
• Richman PB, Garra G, Eskin B, Nashed AH, Cody R. Oral antibiotic use without consulting a physician: a survey of ED patients. Am J Emerg Med 2001;19:57–60
   Google Scholar
• Avorn J, Solomon DH. Cultural and economic factors that (mis)shape antibiotic use: the nonpharmacologic basis of therapeutics. Ann Intern Med 2000;133:128–35
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Murio C, Guerrero T, on behalf of the DAFNE Study Group. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:928–33
   Google Scholar
• Mandell LA, Bartlett JG, Dowell SF, File Jr. TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405–33
   Google Scholar
• Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730–54
   PubMed Web of Science ®Google Scholar
• Torres A, Dorca J, Zalacaín R, et al. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am J Respir Crit Care Med 1996;154:1456–61
   Google Scholar
• Gompertz S, O’Brien C, Bayley DL, Hill SL, Stockley RA. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:1112–9
   PubMed Web of Science ®Google Scholar
• Sethi S, Muscarella K, Evans N, et al. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000;118:1557–65
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449–56
   PubMed Web of Science ®Google Scholar
• Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59–65
   Google Scholar
• Reisner C, Fischer T, Morris M, Zhu J, Barnhart F. Cilomilast reduces exacerbations in COPD patients. Presented at the American College of Chest Physicians Annual Meeting; November 2–7, 2002; San Diego, CA
   Google Scholar
• Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217–24
   PubMed Web of Science ®Google Scholar
• Jarvis B, Markham A. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. Drugs Aging 2001;18:441–72
   PubMed Web of Science ®Google Scholar